Brain and mental health safety of GLP-1 receptor drugs and tirzepatide in adults with type 2 diabetes or obesity

Regulatory reviews by the European Medicines Agency and the US Food and Drug Administration have been prompted by neuropsychiatric safety concerns regarding glucagon-like peptide-1 receptor agonists.

• Glucagon-like peptide-1 receptor agonists are being scrutinized for potential neuropsychiatric risks.
• The evidence synthesized focuses on adults with type 2 diabetes mellitus or obesity.
• Considerations include study design and risk of bias in the findings.
• There is a distinction made between detecting safety signals and establishing causal relationships.

Simplified